Switching from Lopinavir-Ritonavir to Raltegravir

SWITCHMRK 1 & 2 Trials
Switching from Lopinavir-Ritonavir to Raltegravir

SWITCHMRK 1 & 2 Trials: Study Design

Study Design: SWITCHMRK 1&2

- **Background**: Randomized, double-blind, double-dummy trial evaluating switch from lopinavir-ritonavir to raltegravir in combination with background therapy

- **Inclusion Criteria (n = 707 combined)**
  - Age ≥ 18
  - HIV RNA < 50 copies/mL for ≥3 months
  - On lopinavir-ritonavir
  - CD4 count ≥100 cells/mm³
  - No lipid-lowering agent for 12 weeks

- **Treatment Arms**
  - Raltegravir 400 mg BID + background therapy
  - Lopinavir-ritonavir 400-100 mg BID + background therapy

*Background therapy in both groups included at least 2 NRTIs

Switching from Lopinavir-Ritonavir to Raltegravir
SWITCHMRK 1 & 2 Trials: Results

Week 24: Virologic Response (Non-Completion Counted as Failure)

Virologic Failure: Lopinavir-Ritonavir (N = 4); Raltegravir (N = 12)

Switching from Lopinavir-Ritonavir to Raltegravir

SWITCHMRK 1 Trial: Results

SWITCHMRK 1 Week 12: Analysis of Lipids

Switching from Lopinavir-Ritonavir to Raltegravir
SWITCHMRK 2 Trial: Results

SWITCHMRK 2 Week 12: Analysis of Lipids

**Mean Change from Baseline at Week 12 (%)**

- **Total Cholesterol**
  - Raltegravir: -12.4
  - Lopinavir-ritonavir: 1.3

- **Triglycerides**
  - Raltegravir: -42.8
  - Lopinavir-ritonavir: -2.5

- **LDL Cholesterol**
  - Raltegravir: 4.0
  - Lopinavir-ritonavir: 0.6

- **HDL Cholesterol**
  - Raltegravir: -50
  - Lopinavir-ritonavir: -40

Interpretation: “Although switching to raltegravir was associated with greater reductions in serum lipid concentrations than was continuation of lopinavir-ritonavir, efficacy results did not establish non-inferiority of raltegravir to lopinavir-ritonavir.”

Acknowledgment

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.